PMC:7195088 / 1238-1809
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
19 | 89-97 | Species | denotes | patients | Tax:9606 |
20 | 270-278 | Species | denotes | patients | Tax:9606 |
21 | 562-570 | Species | denotes | patients | Tax:9606 |
22 | 103-111 | Disease | denotes | COVID-19 | MESH:C000657245 |
23 | 553-561 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T9 | 103-111 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T10 | 553-561 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 9-14 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 9-14 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T2 | 15-24 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T3 | 29-52 | Chemical | denotes | anti-inflammatory drugs | http://purl.obolibrary.org/obo/CHEBI_35472 |
T4 | 47-52 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T5 | 386-392 | Chemical | denotes | Access | http://purl.obolibrary.org/obo/CHEBI_34922 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T14 | 0-112 | Sentence | denotes | Many off-label antiviral and anti-inflammatory drugs are currently being administered to patients with COVID-19. |
T15 | 113-385 | Sentence | denotes | Physicians must be aware that, as they are not supported by high-level evidence, these treatments may often be ethically justifiable only in those worsening patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. |
T16 | 386-571 | Sentence | denotes | Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients. |